SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC).
Ono Pharmaceutical and twoXAR announced that the companies have signed a drug discovery research collaboration to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease.
twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures, a SoftBank Group early stage venture capital arm.
twoXAR has been named as one of the inaugural MIT Startup Exchange (STEX) STEX25 companies. STEX25 is a select group of industry-ready startups that are actively promoted to members of the MIT Industrial Liaison Program (ILP).
twoXAR has raised $3.4 million in seed financing led by Andreessen Horowitz. twoXAR will use these funds to expand its engineering and commercial teams and advance the progress of new and existing partnerships focused on drug candidates for metabolic and neurological diseases.